Thus, OCT1 expression and activity may be a critical determinant of intracellular drug levels[78]; indeed, the OCT1 expression level has been suggested to be a valuable biomarker for predicting the success of imatinib-based therapy in CML patients[79,80]. Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.